Edition:
United States

FibroGen Inc (FGEN.OQ)

FGEN.OQ on NASDAQ Stock Exchange Global Select Market

57.50USD
23 Feb 2018
Change (% chg)

$1.30 (+2.31%)
Prev Close
$56.20
Open
$56.15
Day's High
$57.60
Day's Low
$55.15
Volume
126,816
Avg. Vol
195,841
52-wk High
$63.00
52-wk Low
$22.80

Latest Key Developments (Source: Significant Developments)

Fibrogen Inc reports Q3 loss per share $0.50
Wednesday, 8 Nov 2017 04:02pm EST 

Nov 8 (Reuters) - Fibrogen Inc ::Fibrogen reports third quarter 2017 financial results.Q3 loss per share $0.50.Q3 earnings per share view $-0.37 -- Thomson Reuters I/B/E/S.nda filing for roxadustat for anemia in​ ckd with u.s. Food and drug administration targeted for 2018.qtrly ‍total revenue $27.3 million versus $30.1 million.  Full Article

Fibrogen announces acceptance by china FDA of roxadustat NDA for treatment of anemia associated with dialysis and non-dialysis kidney disease
Wednesday, 18 Oct 2017 07:00am EDT 

Oct 18 (Reuters) - Fibrogen Inc :Fibrogen announces acceptance by china FDA of roxadustat new drug application (NDA) for treatment of anemia associated with dialysis and non-dialysis chronic kidney disease (CKD).Fibrogen - ‍under terms of Fibrogen's agreement with Astrazeneca, NDA submission triggers a $15 million milestone payment, payable to co by Astrazeneca​.  Full Article

Fibrogen announces pricing of follow-on offering of common stock
Tuesday, 15 Aug 2017 11:31pm EDT 

Aug 15 (Reuters) - Fibrogen Inc - :Fibrogen, Inc. announces pricing of follow-on offering of common stock.Fibrogen Inc - offering 8 million shares of its common stock at an offering price of $40.75 per share, before underwriting discounts and commissions.  Full Article

FibroGen announces proposed follow-on offering of common stock
Monday, 14 Aug 2017 04:26pm EDT 

Aug 14 (Reuters) - Fibrogen Inc :Fibrogen Inc announces proposed follow-on offering of common stock.Fibrogen Inc - ‍intends to offer and sell up to $300 million of its common stock in an underwritten follow-on offering​.Fibrogen Inc - anticipates using net proceeds to fund expansion of product development, manufacturing and commercialization activities​.  Full Article

Fibrogen ‍net loss per diluted share for quarter ended June 30 was $0.48
Monday, 7 Aug 2017 05:47pm EDT 

Aug 7 (Reuters) - Fibrogen Inc :Fibrogen Inc - ‍net loss per basic and diluted share for quarter ended June 30, 2017 was $0.48 - SEC filing​.Fibrogen Inc - ‍at June 30, 2017, Fibrogen had $414.7 million of cash, restricted time deposits, cash equivalents, investments, and receivables​.Q2 earnings per share view $-0.47 -- Thomson Reuters I/B/E/S.Fibrogen Inc - ‍company announces positive topline results from Phase 2 study in IPF​.Fibrogen- ‍pamrevlumab continued to be well tolerated as monotherapy in IPF study, was well tolerated in combination with pirfenidone and nintedanib​.Fibrogen inc - ‍believe that promising outcomes of the studies enable us to advance pamrevlumab into Phase 3 clinical development​.  Full Article

Fibrogen Inc reports Q2 loss per share $0.48
Monday, 7 Aug 2017 04:38pm EDT 

Aug 7 (Reuters) - Fibrogen Inc :Qtrly t‍otal revenue $29 million versus $89.3 million.Fibrogen reports second quarter 2017 financial results.Q2 loss per share $0.48.Q2 earnings per share view $-0.47 -- Thomson Reuters I/B/E/S.Q2 revenue view $34.3 million -- Thomson Reuters I/B/E/S.  Full Article

Fibrogen Inc says ‍European patent office maintains patent relating to HIF technology
Monday, 5 Jun 2017 07:00am EDT 

June 5 (Reuters) - Fibrogen Inc ::‍European patent office maintains fibrogen patent relating to Hypoxia-Inducible Factor (HIF) Prolyl Hydroxylase inhibitor technology​.  Full Article

Fibrogen reports Q1 loss per share $0.52
Tuesday, 9 May 2017 04:02pm EDT 

May 9 (Reuters) - Fibrogen Inc :Fibrogen reports first quarter 2017 financial results.Q1 loss per share $0.52.Q1 earnings per share view $-0.49 -- Thomson Reuters I/B/E/S.Fibrogen Inc - On track to submit NDA for Roxadustat in U.S. in 2018..  Full Article

Fibrogen reports pricing of follow-on offering of common stock
Thursday, 6 Apr 2017 07:00am EDT 

Fibrogen Inc : Fibrogen, Inc. announces pricing of follow-on offering of common stock .Says offering of 5.23 million common shares priced at $22.95 per share.  Full Article

Fibrogen wins China clearance to conduct key study testing roxadustat
Friday, 31 Mar 2017 07:05am EDT 

Fibrogen Inc : Fibrogen announces china fda approval of cta to conduct pivotal phase 2/3 clinical trial of roxadustat in anemia associated with lower risk mds . Fibrogen inc - fibrogen is conducting all clinical trials and regulatory submissions in both u.s. And china . Fibrogen inc - company expects to initiate this phase 2/3 study in second half of 2017 . In addition, company anticipates initiating a u.s. Phase 3 mds clinical trial in q3 of 2017 .Fibrogen inc - fibrogen will retain all regulatory licenses and manufacturing permits in china for roxadustat in anemia associated with lower risk mds.  Full Article

BRIEF-Fibrogen Inc reports Q3 loss per share $0.50

* Q3 earnings per share view $-0.37 -- Thomson Reuters I/B/E/S